The Bristol derivative is worthless as important deadline expires
Pharmaceutical products from Bristol-Myers Squibb Co. Photographer: Daniel Acker / Bloomberg Photographer: Daniel Acker / Bloomberg Investors in a transaction sweetener arose when Bristol-Myers Squ…
